ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Elderly AML & Burkitt Lymphoma Updates"
Episode Synopsis
Aggressive hematologic malignancy publications can be challenging to interpret and translate to clinical practice.
We look at two recent studies to illustrate this point.
Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S2352-3026(23)00273-9)
Burkitt Lymphoma: R-CODXO-M/R-IVAC vs. DA-R-EPOCH (https://doi.org/10.1016/S2352-3026(23)00279-X)
We look at two recent studies to illustrate this point.
Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S2352-3026(23)00273-9)
Burkitt Lymphoma: R-CODXO-M/R-IVAC vs. DA-R-EPOCH (https://doi.org/10.1016/S2352-3026(23)00279-X)
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust